Aligos Therapeutics
ALGS
41 hedge funds and large institutions have $25.5M invested in Aligos Therapeutics in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 13 reducing their positions, and 7 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3.65% less ownership
Funds ownership: 68.71% → 65.06% (-3.7%)
9% less funds holding
Funds holding: 45 → 41 (-4)
46% less capital inflows, than outflows
Capital inflows: $997K | Capital outflows: $1.84M
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
62% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$854K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$60.9K |
| 3 |
Charles Schwab
San Francisco,
California
|
+$33.7K |
| 4 |
Choate Investment Advisors
Boston,
Massachusetts
|
+$25.7K |
| 5 |
Virtu Financial
New York
|
+$19.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Logos Global Management
San Francisco,
California
|
-$874K |
| 2 |
Millennium Management
New York
|
-$244K |
| 3 |
Morgan Stanley
New York
|
-$139K |
| 4 |
NM
Newtyn Management
New York
|
-$130K |
| 5 |
TCM
Tang Capital Management
San Diego,
California
|
-$103K |
ALGS Hedge Fund Activity: Q2 2023 in Review
41 of the 6,388 institutional investors tracked by Wall St. Rank reported a position in Aligos Therapeutics (ALGS) for Q2 2023, worth a combined $25.5M — up 6.8% from $23.9M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of ALGS and 3 opened new positions — a net loss of 4 holders — while 13 trimmed existing stakes and 5 added.
The largest buyer was Royal Bank of Canada, adding an estimated $854K. The largest seller was Logos Global Management, exiting entirely with an estimated $874K sold.
- 41 institutional investors held Aligos Therapeutics (ALGS) as of Q2 2023, down from 45 in Q1 2023.
- Funds reported $25.5M of Aligos Therapeutics stock for Q2 2023, up 6.8% quarter-over-quarter.
- 3 funds opened new Aligos Therapeutics positions in Q2 2023 and 7 closed out, a net change of -4 holders.
- The largest Aligos Therapeutics buyer in Q2 2023 was Royal Bank of Canada, an estimated $854K added.
- The largest Aligos Therapeutics seller in Q2 2023 was Logos Global Management, an estimated $874K sold.
Based on aggregated 13F filings for Q2 2023.